Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Targeted intra-arterial gemcitabine vs. continuation of IV gemcitabine plus nab-paclitaxel following induction with sequential IV gemcitabine plus nab-paclitaxel and radiotherapy for unresectable locally advanced pancreatic cancer (TIGeR-PaC): A randomized phase 3 multicenter study.
Authors
Michael J. Pishvaian
Johns Hopkins University School of Medicine, Washington, DC;
Michael J. Pishvaian , Amer H. Zureikat , Charles D. Lopez , Kenneth Meredith , Emmanuel E. Zervos , Hassan Hatoum , Ki Y. Chung , Daniel James Berg , Antonio Ucar , Ripal T Gandhi , Reza Nazemzadeh , Nainesh Parikh , Paula M. Novelli , Brian Kouri , Christopher Laing , Brian A. Boone , Thor Johnson , Susan Elaine Bates , Ramtin Agah , Karyn A. Goodman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03257033
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr TPS773)
DOI
10.1200/JCO.2023.41.4_suppl.TPS773
Abstract #
TPS773
Poster Bd #
Q9
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Trans-intra-arterial gemcitabine versus continuation of IV gemcitabine and nab-paclitaxel following radiotherapy for locally advanced pancreatic cancer (TIGeR-PaC).
First Author: Michael J. Pishvaian
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Toxicity and efficacy of stereotactic body radiation therapy vs. intensity-modulated radiation therapy for the treatment of locally advanced pancreatic cancer in a phase 3 trial.
First Author: Karyn A. Goodman
Poster
2021 ASCO Annual Meeting
Australasian Gastro-Intestinal Trials Group (AGITG) MASTERPLAN: Randomized phase II study of modified neoadjuvant FOLFIRINOX alone or in combination with stereotactic radiotherapy (SBRT) for patients with high-risk and locally advanced pancreatic cancer.
First Author: Andrew Oar
Poster
2019 Gastrointestinal Cancers Symposium
Pathologic outcomes of systemic therapy followed by stereotactic body radiation therapy (SBRT) for pancreatic cancer (PC) in a novel lateral decubitus treatment position.
First Author: Ethan Song